Palvella Therapeutics, Inc. (PVLA)
NASDAQ:PVLA
Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$130.01
-$0.34(-2.31%)
At close: 4:00 PM EST
$130.01
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$20.20 - $151.18
Previous CloseN/A
Volume11.83K
Average Volume (3M)233.39K
Market Cap
$1.50B
Enterprise Value$1.20B
Total Cash (Recent Filing)$261.85M
Total Debt (Recent Filing)$584.00K
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 13, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.17
Shares Outstanding14,342,844
10 Day Avg. Volume247,467
30 Day Avg. Volume233,393
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-35.60
Forecast
1Y Price Target
$234.89Price Target Upside80.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.55
Revenue Forecast (FY)$26.67K
Bulls Say, Bears Say
Bulls Say
Robust Late-stage Clinical Data And Regulatory MomentumPivotal SELVA and supportive TOIVA results, coupled with Breakthrough/Orphan/Fast Track designations and a planned H2 2026 NDA, create a clearer regulatory path. This materially raises the probability of a first-in-disease approval and the potential for durable market exclusivity in niche rare-disease markets.
Material Cash Runway From Recent Equity FinancingA large, oversubscribed $230M equity raise lifted cash to the low- to mid-$200M range, providing runway to complete regulatory filing, scale manufacturing, hire commercial resources, and fund additional trials. This reduces near-term financing pressure and supports a multi-indication launch strategy.
Low Financial Leverage And Substantial Equity BaseVery low debt and a sizable equity/asset base give the company financial flexibility to invest in commercialization and pipeline expansion without heavy interest expenses. Low leverage reduces refinancing risk and preserves optionality during the transition from clinical-stage to commercial operations.
Bears Say
No Product Revenue And Widening LossesAs a clinical-stage biotech with zero product revenue and escalating net losses, Palvella lacks operating earnings to sustain growth. Long-term value depends on translating clinical success into approved product sales; until then, returns remain negative and the business is financing-dependent.
Accelerating Negative Operating Cash FlowConsistently negative OCF and accelerating cash burn are structural constraints: the company will continue drawing on its cash reserves or capital markets until commercial sales begin. This elevates funding and dilution risk if regulatory or launch timing slips versus plan.
Concentration And Clinical/regulatory Execution RiskPalvella's strategy and near-term value hinge on QTORIN approvals and successful commercialization. Heavy program concentration creates a single-point failure risk: regulatory delays, unexpected safety/efficacy issues, or limited post-approval uptake would materially undermine revenues and long-term viability.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics, Inc.’s price range in the past 12 months?
Palvella Therapeutics, Inc. lowest stock price was $20.20 and its highest was $151.18 in the past 12 months.
What is Palvella Therapeutics, Inc.’s market cap?
Palvella Therapeutics, Inc.’s market cap is $1.50B.
When is Palvella Therapeutics, Inc.’s upcoming earnings report date?
Palvella Therapeutics, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 64 days.
How were Palvella Therapeutics, Inc.’s earnings last quarter?
Palvella Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.2 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.2.
Is Palvella Therapeutics, Inc. overvalued?
According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued.
Does Palvella Therapeutics, Inc. pay dividends?
Palvella Therapeutics, Inc. does not currently pay dividends.
What is Palvella Therapeutics, Inc.’s EPS estimate?
Palvella Therapeutics, Inc.’s EPS estimate is -1.16.
How many shares outstanding does Palvella Therapeutics, Inc. have?
Palvella Therapeutics, Inc. has 14,342,844 shares outstanding.
What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?
Palvella Therapeutics, Inc. reported an EPS of -$1.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.991%.
Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$234.89 (80.67% Upside)
$234.89 (80.67% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
291.92%
12-Months-Change
Fundamentals
Return on Equity
-56.87%
Trailing 12-Months
Asset Growth
232.03%
Trailing 12-Months
Company Description
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q1 2026
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$234.89
▲(80.67% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
―
Tyra Bioscience
―
Ownership Overview
1.92% Insiders
7.19% Mutual Funds
59.12% Other Institutional Investors
22.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---